Select Transactions
|
| Global collaboration for the development and commercialization of ODM-208 with |
|
|
$290 million upfront
July 2022
|
|
| Sale to |
|
|
$260 million
August 2021
|
|
| Sale of 100% equity stake to |
|
|
$106 million + milestones
June 2021
|
|
| Equity investment from |
|
|
$200 million
February 2021
|
Torreya is a leading strategic M&A advisor to global life sciences companies. MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales. MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations. MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals. MORE
The Pharma 1000
Top Global Pharmaceutical Company Report
November 2021
Torreya report provides a snapshot of the global pharmaceutical industry in November 2021.